CGON - Company ID 0001991792
The table below shows CG Oncology, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $1.08M | $1.67M | $0.00 | $52.00K | $43.00K | $111.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $43.73M | $27.88M | $31.33M | $27.47M | $19.62M | $18.47M |
CG Oncology, Inc. reported annual revenue of $4.04M for fiscal year 2025. That is up 254.7% from $1.14M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $20.78M |
| $23.33M |
| $17.41M |
| $14.79M |
| $8.72M |
| $7.49M |
| Operating income | -$66.39M | -$51.13M | -$48.74M | -$42.20M | -$28.30M | -$25.85M |
| Income tax | - | - | - | - | - | - |
| Net income | -$60.20M | -$43.81M | -$41.43M | -$34.45M | -$20.41M | -$18.90M |
| EPS (diluted) | -$0.71 | -$0.57 | -$0.54 | -$0.45 | -$0.30 | -$0.28 |